Monoclonal antibody therapeutics: History and future

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 615-622

  Buss, Nicholas A P S ^a   Henderson, Simon J ^a   McFarlane, Mary ^a   Shenton, Jacintha M ^a   De Haan, Lolke ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANAKINUMAB; CATUMAXOMAB; DACLIZUMAB; DENOSUMAB; DRUG ANTIBODY; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PERTUZUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; USTEKINUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANKYLOSING SPONDYLITIS; ANTIBODY ENGINEERING; ASTHMA; B CELL LYMPHOMA; BONE METASTASIS; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROHN DISEASE; DRUG DEVELOPMENT; DRUG INDICATION; DRUG MARKETING; EUROPE; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; MALIGNANT ASCITES; MELANOMA; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; PROTEIN ENGINEERING;

EID: 84867331959     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.08.001     Document Type: Review

References (58)

1. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
2. R.J. Ober, C.G. Radu, V. Ghetie, and E.S. Ward Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies Int Immunol 13 2001 1551 1559
3. M. Stern, and R. Herrmann Overview of monoclonal antibodies in cancer therapy: present and promise Crit Rev Oncol Hematol 54 2005 11 29
4. S.L. Morrison, M.J. Johnson, L.A. Herzenberg, and V.T. Oi Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc Natl Acad Sci USA 81 1984 6851 6855
5. L.G. Presta Engineering of therapeutic antibodies to minimize immunogenicity and optimize function Adv Drug Deliv Rev 58 2006 640 656
6. P.T. Jones, P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 1986 522 525
7. J. McCafferty, A.D. Griffiths, G. Winter, and D.J. Chiswell Phage antibodies: filamentous phage displaying antibody variable domains Nature 348 1990 552 554
8. G. Winter, A.D. Griffiths, R.E. Hawkins, and H.R. Hoogenboom Making antibodies by phage display technology Annu Rev Immunol 12 1994 433 455
9. T.J. Vaughan, A.J. Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J. McCafferty, R.A. Hodits, J. Wilton, and K.S. Johnson Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library Nat Biotechnol 14 1996 309 314
10. T.J. Vaughan, J.K. Osbourn, and P.R. Tempest Human antibodies by design Nat Biotechnol 16 1998 535 539
11. R.M. Hoet, E.H. Cohen, R.B. Kent, K. Rookey, S. Schoonbroodt, S. Hogan, L. Rem, N. Frans, M. Daukandt, and H. Pieters Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining- region diversity Nat Biotechnol 23 2005 344 348
12. T. Jostock, M. Vanhove, E. Brepoels, R. Van Gool, M. Daukandt, A. Wehnert, R. Van Hegelsom, D. Dransfield, D. Sexton, and M. Devlin Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries J Immunol Methods 289 2004 65 80
13. G.L. Boulianne, N. Hozumi, and M.J. Shulman Production of functional chimaeric mouse/human antibody Nature 312 1984 643 646
14. N. Lonberg, L.D. Taylor, F.A. Harding, M. Trounstine, K.M. Higgins, S.R. Schramm, C.C. Kuo, R. Mashayekh, K. Wymore, and J.G. McCabe Antigen-specific human antibodies from mice comprising four distinct genetic modifications Nature 368 1994 856 859
15. L.L. Green, M.C. Hardy, C.E. Maynard-Currie, H. Tsuda, D.M. Louie, M.J. Mendez, H. Abderrahim, M. Noguchi, D.H. Smith, and Y. Zeng Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs Nat Genet 7 1994 13 21
16. M.P. Baker, H.M. Reynolds, B. Lumicisi, and C.J. Bryson Immunogenicity of protein therapeutics: the key causes, consequences and challenges Self Nonself 1 2010 314 322
17. A.S. De Groot, J. McMurry, and L. Moise Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates Curr Opin Pharmacol 8 2008 620 626
18. N. Lonberg Fully human antibodies from transgenic mouse and phage display platforms Curr Opin Immunol 20 2008 450 459
19. A.L. Nelson, E. Dhimolea, and J.M. Reichert Development trends for human monoclonal antibody therapeutics Nat Rev Drug Discov 9 2010 767 774
20. A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, and K. Shitara Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities Cancer Res 68 2008 3863 3872
21. Z. An, G. Forrest, R. Moore, M. Cukan, P. Haytko, L. Huang, S. Vitelli, J.Z. Zhao, P. Lu, and J. Hua IgG2m4, an engineered antibody isotype with reduced Fc function MAbs 1 2009 572 579
22. R. Abès, and J.L. Teillaud Impact of glycosylation on effector functions of therapeutic IgG Pharmaceuticals 3 2010 146 157
23. W.R. Strohl Optimization of Fc-mediated effector functions of monoclonal antibodies Curr Opin Biotechnol 20 2009 685 691
24. A.C. Chan, and P.J. Carter Therapeutic antibodies for autoimmunity and inflammation Nat Rev Immunol 10 2010 301 316
25. P.R. Hinton, M.G. Johlfs, J.M. Xiong, K. Hanestad, K.C. Ong, C. Bullock, S. Keller, M.T. Tang, J.Y. Tso, and M. Vásquez Engineered human IgG antibodies with longer serum half-lives in primates J Biol Chem 279 2004 6213 6216
26. P.R. Hinton, J.M. Xiong, M.G. Johlfs, M.T. Tang, S. Keller, and N. Tsurushita An engineered human IgG1 antibody with longer serum half-life J Immunol 176 2006 346 356
27. W.F. Dall'Acqua, P.A. Kiener, and H. Wu Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) J Biol Chem 281 2006 23514 23524
28. J.G. Salfeld Isotype selection in antibody engineering Nat Biotechnol 25 2007 1369 1372
29. N.M. Stapleton, J.T. Andersen, A.M. Stemerding, S.P. Bjarnarson, R.C. Verheul, J. Gerritsen, Y. Zhao, M. Kleijer, I. Sandlie, and M. de Haas Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential Nat Commun 2 2011 599
30. R.C. Aalberse, and J. Schuurman IgG4 breaking the rules Immunology 105 2002 9 19
31. A.F. Labrijn, A.O. Buijsse, E.T. van den Bremer, A.Y. Verwilligen, W.K. Bleeker, S.J. Thorpe, J. Killestein, C.H. Polman, R.C. Aalberse, and J. Schuurman Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo Nat Biotechnol 27 2009 767 771
32. J.W. Bloom, M.S. Madanat, D. Marriott, T. Wong, and S.Y. Chan Intrachain disulfide bond in the core hinge region of human IgG4 Protein Sci 6 1997 407 415
33. Y. Lu, S.E. Harding, A.J. Rowe, K.G. Davis, B. Fish, P. Varley, C. Gee, and S. Mulot The effect of a point mutation on the stability of IgG4 as monitored by analytical ultracentrifugation J Pharm Sci 97 2008 960 969
34. S. Webb Pharma interest surges in antibody drug conjugates Nat Biotechnol 29 2011 297 298
35. L. DeFrancesco Seattle genetics rare cancer drug sails through accelerated approval Nat Biotechnol 29 2011 851 852
36. T.T. Junttila, G. Li, K. Parsons, G.L. Phillips, and M.X. Sliwkowski Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res Treat 128 2011 347 356
37. P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, and D. Shochat Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug Chem 13 2002 47 58
38. R.J. Sanderson, M.A. Hering, S.F. James, M.M. Sun, S.O. Doronina, A.W. Siadak, P.D. Senter, and A.F. Wahl In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin Cancer Res 11 2005 843 852
39. S.C. Alley, D.R. Benjamin, S.C. Jeffrey, N.M. Okeley, D.L. Meyer, R.J. Sanderson, and P.D. Senter Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjug Chem 19 2008 759 765
40. B.Q. Shen, K. Xu, L. Liu, H. Raab, S. Bhakta, M. Kenrick, K.L. Parsons-Reponte, J. Tien, S.F. Yu, and E. Mai Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat Biotechnol 30 2012 184 189
41. R.Y. Zhao, S.D. Wilhelm, C. Audette, G. Jones, B.A. Leece, A.C. Lazar, V.S. Goldmacher, R. Singh, Y. Kovtun, and W.C. Widdison Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates J Med Chem 54 2011 3606 3623
42. M.W. Pedersen, H.J. Jacobsen, K. Koefoed, A. Hey, C. Pyke, J.S. Haurum, and M. Kragh Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res 70 2010 588 597
43. R. Mabry, and M. Snavely Therapeutic bispecific antibodies: the selection of stable single-chain fragments to overcome engineering obstacles IDrugs 13 2010 543 549
44. D. Müller, and R.E. Kontermann Bispecific antibodies for cancer immunotherapy current perspectives BioDrugs 24 2010 89 98
45. R. Linke, A. Klein, and D. Seimetz Catumaxomab: clinical development and future directions MAbs 2 2010 129 136
46. U.D. Staerz, O. Kanagawa, and M.J. Bevan Hybrid antibodies can target sites for attack by T cells Nature 314 1985 628 631
47. P.A. Baeuerle, P. Kufer, and R. Bargou BiTE: teaching antibodies to eng age T-cells for cancer therapy Curr Opin Mol Ther 11 2009 22 30
48. W.A. Banks, B. Terrell, S.A. Farr, S.M. Robinson, N. Nonaka, and J.E. Morley Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease Peptides 23 2002 2223 2226
49. B.C. Pestalozzi, and S. Brignoli Trastuzumab in CSF J Clin Oncol 18 2000 2349 2351
50. H.J. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck, and V. Heinemann Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anticancer Drugs 18 2007 23 28
51. R.T. Frank, K.S. Aboody, and J. Najbauer Strategies for enhancing antibody delivery to the brain Biochim Biophys Acta 1816 2011 191 198
52. M.M. Patel, B.R. Goyal, S.V. Bhadada, J.S. Bhatt, and A.F. Amin Getting into the brain: approaches to enhance brain drug delivery CNS Drugs 23 2009 35 58
53. G.A. Silva Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS BMC Neurosci 10 9 Suppl. 3 2008 S4
54. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J.M. Elliott, S. Prabhu, R.J. Watts, and M.S. Dennis Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci Transl Med 3 2011 84ra44
55. R.J. Boado, J.Z. Lu, E.K. Hui, and W.M. Pardridge IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey Biotechnol Bioeng 105 2010 627 635
56. A. Abulrob, H. Sprong, P. Van Bergen en Henegouwen, and D. Stanimirovic The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells J Neurochem 95 2005 1201 1214
57. K.S. Rutgers, R.J. Nabuurs, S.A. van den Berg, G.J. Schenk, M. Rotman, C.T. Verrips, S.G. van Duinen, M.L. Maat-Schieman, M.A. van Buchem, and A.G. de Boer Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier Neuroscience 190 2011 37 42
58. F.W. Brambell, W.A. Hemmings, and I.G. Morris A theoretical model of gamma-globulin catabolism Nature 203 1964 1352 1354